Article and Video CATEGORIES

Cancer Journey

Search By

Management of Locally Advanced NSCLC in the Elderly and Frail
Wed, 02/10/2016 - 06:00
Author
GRACE Videos and Articles
GRACE Cancer Video Library - Lung

GCVL_LU-EA02_Mark_Socinski_WCLC_6

 

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

 

Download Transcript

 

Transcript

A substantial portion of our patients are over the age of 70, and this disease is still often associated with smoking, so the older patients tend to have more comorbidities, and often may have a frailness to them at the time of diagnosis. All the paradigms that we’ve been talking about — chemoradiation, surgical excision, certainly have a toxicity associated with them, and surgery has a risk of morbidity and mortality associated with it. So I think special consideration needs to be made to those elderly, frail patients which have been largely underrepresented in many clinical trials because they would have been excluded based on comorbidities or performance status, and therefore you can’t necessarily apply the paradigms defined in published clinical trials to this population.

It is very clear that, for instance, in the chemoradiation world, the standard of care is concurrent use of chemoradiation. This substantially increases the risk of certain toxicities such as esophagitis, myelosuppression, and fatigue, and may be very debilitating in an elderly, frail patient. So one must consider: is this the best treatment for that particular patient? In many patients, we may give a brief course, two to three cycles, of chemotherapy to see how they tolerate it, and then consider following it if they tolerate it well, and if they have a response, particularly with radiotherapy. Often we give that radiotherapy alone, or sometimes we give it with a low dose of chemotherapy during the radiation with a regimen such as carboplatinum and paclitaxel.

So that’s a very common approach at our institution. Alternatively, patients may start with concurrent radiotherapy, or we may start some frail patients who may have very symptomatic disease, who may have impending obstruction of a bronchus or something like that in the medial part of the chest — often we may start them with radiotherapy alone with the intent to palliate their symptoms, to relieve the obstruction as best we can, and then again, if patents do well with initial radiotherapy, follow it up with systemic therapy following this — assuming that the patient’s condition improves as a result of the initial radiotherapy.

So, I don’t know in this population of elderly, frail patients that there’s a one size that fits all. I think one has to review the CT scans, examine the patient, get an idea of how symptomatic the patient is and what the symptoms are. I do think the strategy of chemotherapy alone, followed by radiation, or sequential strategy is something that we do quite often in this population. I think that concurrent chemoradiotherapy can be done with low dose strategies in an eldery, frail population, and actually may be a reasonable strategy if you have local/regional issues that need attention, such as impending bronchial obstruction would be the best example there. We do know that adding chemotherapy to radiation does lead to better regional control in the area, or the field of radiation. So again, I think one has to personalize and customize the treatment for this elderly, frail population.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Mandarin LCVL
Video
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit: https://www.youtube.com/playlist?list=PLWsyUmdjLXhGnSxobmz4CBP3pxAj7nDa…;  
Image
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
Article
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Image
Blood Cancer OncTalk
Video
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Recent Comments

JOIN THE CONVERSATION
Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
Concerned
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29